REFERENCES
- Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25: 3065–3083
- , DuffGCommittee on safety of medicine: Strattera (atomoxetine)—risk of hepatic disorders 2 February 2005. Accessed 23 June 2005. http://www.mhra.gov.uk/news/February/straterra_healthprof.pdf
- , Eli Lilly and Company. Lilly news – financial news release. 18 April 2005. Accessed 23 June 2005. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=160474
- 4. Eli Lilly and Company. Strattera® (atomoxetine) prescribing information, data on file. Indianapolis, IN, 2004.
- Lee WM. Review article – drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474–485
- Feldman M, Friedman LS, Sleisenger MH. Liver diseases caused by drugs, anesthetics, and toxins. In. Gastrointestinal and Liver Disease. W.B. Saunders Company, Philadelphia 2002; 1403–1447
- Colle I, Naegels S, Hoorens A, Hautekeete M. Granulomatous hepatitis due to mebendazole. J Clin Gastroenterol 1999; 18: 44–48
- Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgrad Med 1974; 56: 193–195
- Danan G, Benichou C. Causality assessment of adverse reactions to drugs 1. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–1330
- Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3: 329–344
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245
- Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 53–63
- De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP 450 2C19. Psychosomatics 2006; 47: 75–85
- Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31: 98–107